{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T13:07:09Z","timestamp":1792069629448,"version":"4.4.0"},"reference-count":106,"publisher":"BMJ","issue":"5","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Gut"],"accepted":{"date-parts":[[2020,1,11]]},"published-print":{"date-parts":[[2020,5]]},"abstract":"<jats:p>In the recent years, there have been an increasing number of reports on favourable effects of statins in patients with advanced chronic liver disease. These include reduction in portal pressure, improved liver sinusoidal endothelial and hepatic microvascular dysfunction, decreased fibrogenesis, protection against ischaemia\/reperfusion injury, safe prolongation of ex vivo liver graft preservation, reduced sensitivity to endotoxin-mediated liver damage, protection from acute-on-chronic liver failure, prevention of liver injury following hypovolaemic shock and preventing\/delaying progression of cirrhosis of any aetiology. Moreover, statins have been shown to have potential beneficial effects in the progression of other liver diseases, such as chronic sclerosing cholangitis and in preventing hepatocellular carcinoma. Because of these many theoretically favourable effects, statins have evolved from being considered a risk to kind of wonder drugs for patients with chronic liver diseases. The present article reviews the current knowledge on the potential applications of statins in chronic liver diseases, from its mechanistic background to objective evidence from clinical studies.<\/jats:p>","DOI":"10.1136\/gutjnl-2019-318237","type":"journal-article","created":{"date-parts":[[2020,3,5]],"date-time":"2020-03-05T17:15:50Z","timestamp":1583428550000},"page":"953-962","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":130,"title":["Cirrhosis as new indication for statins"],"prefix":"10.1136","volume":"69","clinical-trial-number":[{"clinical-trial-number":"nct01282398","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03654053","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03780673","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3414-0055","authenticated-orcid":false,"given":"Jaime","family":"Bosch","sequence":"first","affiliation":[{"name":"Inselspital Universitatsspital Bern, Bern, Switzerland"},{"name":"Institut d'Investigacions Biomediques August Pi i Sunyer, Barcelona, Spain"},{"name":"CIBEREHD, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7736-4089","authenticated-orcid":false,"given":"Jordi","family":"Gracia-Sancho","sequence":"additional","affiliation":[{"name":"Inselspital Universitatsspital Bern, Bern, Switzerland"},{"name":"Institut d'Investigacions Biomediques August Pi i Sunyer, Barcelona, Spain"},{"name":"CIBEREHD, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan G","family":"Abraldes","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology (Liver Unit), University of Alberta, Edmonton, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,3,5]]},"reference":[{"key":"2025112110591182000_69.5.953.1","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1053\/j.gastro.2010.10.031","article-title":"Prolonging survival in patients with cirrhosis: old drugs with new indications","volume":"139","author":"Tsochatzis","year":"2010","journal-title":"Gastroenterology"},{"key":"2025112110591182000_69.5.953.2","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1038\/nrgastro.2015.78","article-title":"Statins and liver disease: from concern to 'wonder' drugs?","volume":"12","author":"Bosch","year":"2015","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2025112110591182000_69.5.953.3","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1002\/hep.29277","article-title":"Statins in cirrhosis-Ready for prime time","volume":"66","author":"Tsochatzis","year":"2017","journal-title":"Hepatology"},{"key":"2025112110591182000_69.5.953.4","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-015-4000-6"},{"key":"2025112110591182000_69.5.953.5","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/jgh.12657","article-title":"Severe hepatic injury associated with different statins in patients with chronic liver disease: a nationwide population-based cohort study","volume":"30","author":"Chang","year":"2015","journal-title":"J Gastroenterol Hepatol"},{"key":"2025112110591182000_69.5.953.6","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2016.06.055","article-title":"Altered pharmacokinetics of statins explain increased risk of rhabdomyolysis in advanced cirrhosis","volume":"151","author":"Weersink","year":"2016","journal-title":"Gastroenterology"},{"key":"2025112110591182000_69.5.953.7","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2016.01.004"},{"key":"2025112110591182000_69.5.953.8","doi-asserted-by":"crossref","DOI":"10.1007\/s11894-017-0584-7","article-title":"Use of statins in patients with chronic liver disease and cirrhosis: current views and prospects","volume":"19","author":"Vargas","year":"2017","journal-title":"Curr Gastroenterol Rep"},{"key":"2025112110591182000_69.5.953.9","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/j.cgh.2017.04.039","article-title":"Statin use and risk of cirrhosis and related complications in patients with chronic liver diseases: a systematic review and meta-analysis","volume":"15","author":"Kim","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025112110591182000_69.5.953.10","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1053\/j.gastro.2018.07.022","article-title":"Simvastatin prevents progression of acute on chronic liver failure in rats with cirrhosis and portal hypertension","volume":"155","author":"Tripathi","year":"2018","journal-title":"Gastroenterology"},{"key":"2025112110591182000_69.5.953.11","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.jhep.2018.07.019","article-title":"Statins: old drugs as new therapy for liver diseases?","volume":"70","author":"Pose","year":"2019","journal-title":"J Hepatol"},{"key":"2025112110591182000_69.5.953.12","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1007\/s11938-018-0180-4","article-title":"The use of statins in patients with chronic liver disease and cirrhosis","volume":"16","author":"Moctezuma-Vel\u00e1zquez","year":"2018","journal-title":"Curr Treat Options Gastroenterol"},{"key":"2025112110591182000_69.5.953.13","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1016\/j.cgh.2018.11.002","article-title":"Statin use is associated with improved outcomes of patients with primary sclerosing cholangitis","volume":"17","author":"Stokkeland","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025112110591182000_69.5.953.14","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28506"},{"key":"2025112110591182000_69.5.953.15","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/hep.28537","article-title":"Stat order: should patients with chronic liver disease be prescribed statins to prevent fibrosis progression and hepatocellular carcinoma?","volume":"64","author":"Abraldes","year":"2016","journal-title":"Hepatology"},{"key":"2025112110591182000_69.5.953.16","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-01-0046"},{"key":"2025112110591182000_69.5.953.17","doi-asserted-by":"publisher","DOI":"10.1172\/JCI24787"},{"key":"2025112110591182000_69.5.953.18","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.jhep.2016.07.051","article-title":"Cross-Talk between autophagy and KLF2 determines endothelial cell phenotype and microvascular function in acute liver injury","volume":"66","author":"Guix\u00e9-Muntet","year":"2017","journal-title":"J Hepatol"},{"key":"2025112110591182000_69.5.953.19","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2010.220913"},{"key":"2025112110591182000_69.5.953.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2012.08.026"},{"key":"2025112110591182000_69.5.953.21","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2014-308338"},{"key":"2025112110591182000_69.5.953.22","doi-asserted-by":"crossref","unstructured":"Hide D , Warren A , Fern\u00e1ndez-Iglesias A , et al . Ischemia\/Reperfusion injury in the aged liver: the importance of the sinusoidal endothelium in developing therapeutic strategies for the elderly. J Gerontol A Biol Sci Med Sci 2019;59.doi:10.1093\/gerona\/glz012","DOI":"10.1093\/gerona\/glz012"},{"key":"2025112110591182000_69.5.953.23","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2005.081059"},{"key":"2025112110591182000_69.5.953.24","doi-asserted-by":"publisher","DOI":"10.1038\/nrd1901"},{"key":"2025112110591182000_69.5.953.25","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21673"},{"key":"2025112110591182000_69.5.953.26","first-page":"10","article-title":"Hepatic ischemia and reperfusion injury: effects on the liver sinusoidal milieu","volume":"13","author":"Peralta","year":"2013","journal-title":"JHepatol"},{"key":"2025112110591182000_69.5.953.27","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-200102270-00008"},{"key":"2025112110591182000_69.5.953.28","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1097\/TP.0b013e3181e228db","article-title":"Flow cessation triggers endothelial dysfunction during organ cold storage conditions: strategies for pharmacologic intervention","volume":"90","author":"Gracia-Sancho","year":"2010","journal-title":"Transplantation"},{"key":"2025112110591182000_69.5.953.29","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S1734-1140(10)70274-7","article-title":"Effect of simvastatin on nitric oxide synthases (eNOS, iNOS) and arginine and its derivatives (ADMA, SDMA) in ischemia\/reperfusion injury in rat liver","volume":"62","author":"Trocha","year":"2010","journal-title":"Pharmacological Reports"},{"key":"2025112110591182000_69.5.953.30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2013.02.005"},{"key":"2025112110591182000_69.5.953.31","doi-asserted-by":"crossref","DOI":"10.1038\/srep22107","article-title":"Effects of warm ischemia and reperfusion on the liver microcirculatory phenotype of rats: underlying mechanisms and pharmacological therapy","volume":"6","author":"Hide","year":"2016","journal-title":"Sci Rep"},{"key":"2025112110591182000_69.5.953.32","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24755"},{"key":"2025112110591182000_69.5.953.33","doi-asserted-by":"crossref","unstructured":"Meireles CZ , Pasarin M , Lozano JJ , et al . Simvastatin attenuates liver injury in rodents with biliary cirrhosis submitted to Hemorrhage\/Resuscitation. Shock 2016.","DOI":"10.1097\/SHK.0000000000000734"},{"key":"2025112110591182000_69.5.953.34","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-008-8091-0"},{"key":"2025112110591182000_69.5.953.35","doi-asserted-by":"publisher","DOI":"10.1097\/00024382-199407000-00001"},{"key":"2025112110591182000_69.5.953.36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcrc.2010.02.013"},{"key":"2025112110591182000_69.5.953.37","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26127"},{"key":"2025112110591182000_69.5.953.38","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.jss.2009.03.057","article-title":"Simvastatin attenuates hepatic sensitization to lipopolysaccharide after partial hepatectomy","volume":"162","author":"Slotta","year":"2010","journal-title":"J Surg Res"},{"key":"2025112110591182000_69.5.953.39","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.jss.2012.08.019","article-title":"Effects of statins on liver cell function and inflammation in septic rats","volume":"178","author":"Stolf","year":"2012","journal-title":"J Surg Res"},{"key":"2025112110591182000_69.5.953.40","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2007.01.020"},{"key":"2025112110591182000_69.5.953.41","doi-asserted-by":"crossref","unstructured":"Trebicka J , Hennenberg M , Odenthal M , et al . Atorvastatin attenuates hepatic fibrosis in rats after bile duct ligation via decreased turnover of hepatic stellate cells. J Hepatol. In Press 2010.","DOI":"10.1016\/j.jhep.2010.04.025"},{"key":"2025112110591182000_69.5.953.42","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.2009.06159.x"},{"key":"2025112110591182000_69.5.953.43","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/S1474-4422(11)70144-2","article-title":"Simvastatin as add-on therapy to interferon beta-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial","volume":"10","author":"Sorensen","year":"2011","journal-title":"The Lancet Neurology"},{"key":"2025112110591182000_69.5.953.44","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-012-6513-7"},{"key":"2025112110591182000_69.5.953.45","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0086663","article-title":"Atorvastatin added to interferon beta for relapsing multiple sclerosis: 12-month treatment extension of the randomized multicenter SWABIMS trial","volume":"9","author":"Kamm","year":"2014","journal-title":"PLoS One"},{"key":"2025112110591182000_69.5.953.46","doi-asserted-by":"crossref","first-page":"2822","DOI":"10.1016\/j.ejca.2014.08.005","article-title":"Simvastatin plus capecitabine\u2013cisplatin versus placebo plus capecitabine\u2013cisplatin in patients with previously untreated advanced gastric cancer: a double-blind randomised phase 3 study","volume":"50","author":"Kim","year":"2014","journal-title":"Eur J Cancer"},{"key":"2025112110591182000_69.5.953.47","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-013-2328-1"},{"key":"2025112110591182000_69.5.953.48","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-2525"},{"key":"2025112110591182000_69.5.953.49","doi-asserted-by":"crossref","first-page":"3200","DOI":"10.1016\/j.ejca.2010.07.036","article-title":"The addition of pravastatin to chemotherapy in advanced gastric carcinoma: a randomised phase II trial","volume":"46","author":"Konings","year":"2010","journal-title":"Eur J Cancer"},{"key":"2025112110591182000_69.5.953.50","doi-asserted-by":"publisher","DOI":"10.1158\/1940-6207.CAPR-13-0189"},{"key":"2025112110591182000_69.5.953.51","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1007\/s10067-014-2654-7","article-title":"Atorvastatin effect on systemic lupus erythematosus disease activity: a double-blind randomized clinical trial","volume":"33","author":"Fatemi","year":"2014","journal-title":"Clin Rheumatol"},{"key":"2025112110591182000_69.5.953.52","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1401520"},{"key":"2025112110591182000_69.5.953.53","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201209-1718OC"},{"key":"2025112110591182000_69.5.953.54","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.280031"},{"key":"2025112110591182000_69.5.953.55","doi-asserted-by":"publisher","DOI":"10.1186\/cc11895"},{"key":"2025112110591182000_69.5.953.56","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201006-0955OC"},{"key":"2025112110591182000_69.5.953.57","doi-asserted-by":"crossref","first-page":"211","DOI":"10.2147\/COPD.S76061","article-title":"Cardiovascular and inflammatory effects of simvastatin therapy in patients with COPD: a randomized controlled trial","volume":"10","author":"John","year":"2015","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2025112110591182000_69.5.953.58","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1403086"},{"key":"2025112110591182000_69.5.953.59","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1056\/NEJMoa1403285","article-title":"Simvastatin in the acute respiratory distress syndrome","volume":"371","author":"McAuley","year":"2014","journal-title":"N Engl J Med Overseas Ed"},{"key":"2025112110591182000_69.5.953.60","doi-asserted-by":"crossref","first-page":"11","DOI":"10.20452\/pamw.869","article-title":"The influence of simvastatin on selected inflammatory markers in patients with chronic obstructive pulmonary disease","volume":"120","author":"Kaczmarek","year":"2010","journal-title":"Pol Arch Med Wewn"},{"key":"2025112110591182000_69.5.953.61","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1042\/CS20080241","article-title":"Effects of pravastatin on functional capacity in patients with chronic obstructive pulmonary disease and pulmonary hypertension","volume":"116","author":"Lee","year":"2009","journal-title":"Clin Sci"},{"key":"2025112110591182000_69.5.953.62","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e318228bf11"},{"key":"2025112110591182000_69.5.953.63","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181d6476a"},{"key":"2025112110591182000_69.5.953.64","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s12664-013-0420-4","article-title":"Randomized clinical trial: atorvastatin versus placebo in patients with acute exacerbation of mild to moderate ulcerative colitis","volume":"33","author":"Dhamija","year":"2014","journal-title":"Indian J Gastroenterol"},{"key":"2025112110591182000_69.5.953.65","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(13)70227-8"},{"key":"2025112110591182000_69.5.953.66","doi-asserted-by":"crossref","unstructured":"Dickerman BA , Garcia-Albeniz X , Logan RW , et al . Avoidable flaws in observational analyses: an application to statins and cancer. Nat Med 2019.","DOI":"10.1038\/s41591-019-0597-x"},{"key":"2025112110591182000_69.5.953.67","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2003.12.007"},{"key":"2025112110591182000_69.5.953.68","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(03)00909-0"},{"key":"2025112110591182000_69.5.953.69","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2009.01.043"},{"key":"2025112110591182000_69.5.953.70","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2015.07.156"},{"key":"2025112110591182000_69.5.953.71","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1097\/MEG.0000000000001006","article-title":"Effects of atorvastatin on portal hemodynamics and clinical outcomes in patients with cirrhosis with portal hypertension","volume":"30","author":"Bishnu","year":"2018","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2025112110591182000_69.5.953.72","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1002\/hep.30314","article-title":"Prioritization of therapeutic targets and trial design in cirrhotic portal hypertension","volume":"69","author":"Abraldes","year":"2019","journal-title":"Hepatology"},{"key":"2025112110591182000_69.5.953.73","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.05.022"},{"key":"2025112110591182000_69.5.953.74","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2013.02.042"},{"key":"2025112110591182000_69.5.953.75","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.jhep.2017.10.018","article-title":"Statin use and the risk of hepatocellular carcinoma in patients at high risk: a nationwide nested case-control study","volume":"68","author":"Kim","year":"2018","journal-title":"J Hepatol"},{"key":"2025112110591182000_69.5.953.76","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1053\/j.gastro.2019.01.026","article-title":"Effects of hypercholesterolemia and statin exposure on survival in a large national cohort of patients with cirrhosis","volume":"156","author":"Kaplan","year":"2019","journal-title":"Gastroenterology"},{"key":"2025112110591182000_69.5.953.77","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1053\/j.gastro.2015.10.007","article-title":"Statins are associated with a decreased risk of decompensation and death in veterans with hepatitis C\u2013Related compensated cirrhosis","volume":"150","author":"Mohanty","year":"2016","journal-title":"Gastroenterology"},{"key":"2025112110591182000_69.5.953.78","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2012.10.005"},{"key":"2025112110591182000_69.5.953.79","doi-asserted-by":"crossref","first-page":"318","DOI":"10.7326\/M18-2753","article-title":"Lipophilic statins and risk for hepatocellular carcinoma and death in patients with chronic viral hepatitis: results from a nationwide Swedish population","volume":"171","author":"Simon","year":"2019","journal-title":"Ann Intern Med"},{"key":"2025112110591182000_69.5.953.80","doi-asserted-by":"publisher","DOI":"10.1054\/bjoc.2000.1716"},{"key":"2025112110591182000_69.5.953.81","first-page":"1099","article-title":"Treatment of HCC with pravastatin, octreotide, or gemcitabine-a critical evaluation","volume":"51","author":"Lersch","year":"2004","journal-title":"Hepatogastroenterology"},{"key":"2025112110591182000_69.5.953.82","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(18)30601-9","article-title":"Results of the phase II randomized French trial PRODIGE 21 comparing sorafenib vs pravastatin vs sorafenib and pravastatin vs best supportive care for the palliative treatment of HCC in child B cirrhotic patients","volume":"68","author":"Blanc","year":"2018","journal-title":"J Hepatol"},{"key":"2025112110591182000_69.5.953.83","doi-asserted-by":"publisher","DOI":"10.1055\/s-0035-1562943"},{"key":"2025112110591182000_69.5.953.84","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.jhep.2017.07.027","article-title":"Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD","volume":"67","author":"Hagstr\u00f6m","year":"2017","journal-title":"J Hepatol"},{"key":"2025112110591182000_69.5.953.85","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1002\/hep.29085","article-title":"Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis","volume":"65","author":"Dulai","year":"2017","journal-title":"Hepatology"},{"key":"2025112110591182000_69.5.953.86","doi-asserted-by":"crossref","first-page":"246","DOI":"10.2174\/1570161115666170621082910","article-title":"Statins: an under-appreciated asset for the prevention and the treatment of NAFLD or NASH and the related cardiovascular risk","volume":"16","author":"Athyros","year":"2018","journal-title":"Curr Vasc Pharmacol"},{"key":"2025112110591182000_69.5.953.87","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.05.006"},{"key":"2025112110591182000_69.5.953.88","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgast-2015-000075","article-title":"Statins, antidiabetic medications and liver histology in patients with diabetes with non-alcoholic fatty liver disease","volume":"3","author":"Nascimbeni","year":"2016","journal-title":"BMJ Open Gastroenterol"},{"key":"2025112110591182000_69.5.953.89","doi-asserted-by":"crossref","first-page":"7860","DOI":"10.3748\/wjg.v21.i25.7860","article-title":"Resolution of non-alcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic syndrome","volume":"21","author":"Kargiotis","year":"2015","journal-title":"WJG"},{"key":"2025112110591182000_69.5.953.90","doi-asserted-by":"publisher","DOI":"10.1111\/liv.13308"},{"key":"2025112110591182000_69.5.953.91","doi-asserted-by":"publisher","DOI":"10.1097\/00004836-200609000-00018"},{"key":"2025112110591182000_69.5.953.92","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2004.02.015"},{"key":"2025112110591182000_69.5.953.93","unstructured":"U.S. Food and Drug Administration (FDA) . Fda drug safety communication: important safety label changes to cholesterol-lowering statin drugs. Rockville, MD, 2012. Available: http:\/\/www.fda.gov\/drugs\/drugsafety\/ucm293101.htm"},{"key":"2025112110591182000_69.5.953.94","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21848"},{"key":"2025112110591182000_69.5.953.95","doi-asserted-by":"publisher","DOI":"10.1001\/jama.292.11.1307"},{"key":"2025112110591182000_69.5.953.96","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60310-8"},{"key":"2025112110591182000_69.5.953.97","doi-asserted-by":"crossref","first-page":"E17","DOI":"10.1111\/j.1530-0277.2012.01901.x","article-title":"Association of liver stiffness with hepatic expression of pharmacokinetically important genes in alcoholic liver disease","volume":"37","author":"Theile","year":"2013","journal-title":"Alcoholism"},{"key":"2025112110591182000_69.5.953.98","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.112.049676"},{"key":"2025112110591182000_69.5.953.99","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0801936"},{"key":"2025112110591182000_69.5.953.100","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000001268","article-title":"Association between SLCO1B1 gene T521C polymorphism and Statin-Related myopathy risk: a meta-analysis of case-control studies","volume":"94","author":"Hou","year":"2015","journal-title":"Medicine"},{"key":"2025112110591182000_69.5.953.101","doi-asserted-by":"crossref","unstructured":"Pose E , Napoleone L , Amin A , et al . Safety of two different doses of simvastatin plus rifaximin in decompensated cirrhosis (LIVERHOPE-SAFETY): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Gastroenterol Hepatol 2019.","DOI":"10.1016\/S2468-1253(19)30320-6"},{"key":"2025112110591182000_69.5.953.102","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199753050-00011"},{"key":"2025112110591182000_69.5.953.103","doi-asserted-by":"publisher","DOI":"10.1136\/flgastro-2014-100500"},{"key":"2025112110591182000_69.5.953.104","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.jhep.2019.04.021","article-title":"Pravastatin combination with sorafenib does not improve survival in advanced hepatocellular carcinoma","volume":"71","author":"Jouve","year":"2019","journal-title":"J Hepatol"},{"key":"2025112110591182000_69.5.953.105","doi-asserted-by":"crossref","first-page":"375S","DOI":"10.1093\/ajh\/6.11.375S","article-title":"Pharmacokinetics of fluvastatin and specific drug interactions","volume":"6","author":"Smith","year":"1993","journal-title":"Am J Hypertens"},{"key":"2025112110591182000_69.5.953.106","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s00228-002-0541-7","article-title":"Pharmacokinetics and pharmacodynamics of rosuvastatin in subjects with hepatic impairment","volume":"58","author":"Simonson","year":"2003","journal-title":"Eur J Clin Pharmacol"}],"container-title":["Gut"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/gutjnl-2019-318237","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T18:59:24Z","timestamp":1763751564000},"score":1,"resource":{"primary":{"URL":"https:\/\/gut.bmj.com\/lookup\/doi\/10.1136\/gutjnl-2019-318237"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,5]]},"references-count":106,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2020,4,3]]},"published-print":{"date-parts":[[2020,5]]}},"alternative-id":["10.1136\/gutjnl-2019-318237"],"URL":"https:\/\/doi.org\/10.1136\/gutjnl-2019-318237","relation":{},"ISSN":["0017-5749","1468-3288"],"issn-type":[{"value":"0017-5749","type":"print"},{"value":"1468-3288","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,5]]}}}